• Microglial Activation and Seizure Risk in Acute Alcohol Expo

  2026-06-04

  The referenced study uncovers how acute alcohol exposure triggers microglial activation in the hippocampal CA1 region, leading to neuronal dysregulation and increased seizure susceptibility. These findings clarify the mechanism by which microglia modulate synaptic balance, offering new directions for targeting neuroinflammatory pathways in seizure research.

• circRNA hsa_circ_0001944 Modulates FXR/TLR4 and Ferroptosis

  2026-06-04

  This study demonstrates that hsa_circ_0001944 alleviates nickel oxide nanoparticle-induced collagen deposition in hepatic stellate cells by regulating the FXR/TLR4 pathway and ferroptosis. The findings provide new mechanistic insight into non-coding RNA-mediated modulation of nuclear receptor signaling and cell death in liver fibrosis, advancing the field's understanding of nanoparticle hepatotoxicity.

• MMP7 Drives EMT-Linked Liver Fibrosis via E-cadherin/β-Caten

  2026-06-03

  This study elucidates how matrix metalloproteinase 7 (MMP7) accelerates liver fibrosis in biliary atresia by promoting epithelial–mesenchymal transition (EMT) via E-cadherin cleavage and β-catenin signaling activation. The findings highlight MMP7 as a mechanistic and potentially therapeutic target for progressive fibrosis in this pediatric disease.

• Cefoperazone Sodium Salt: Optimizing Antibacterial Assays

  2026-06-03

  Cefoperazone sodium salt stands out for its potent, β-lactamase-stable activity against gram-negative bacilli and its pivotal role in resistance modeling. This guide translates benchmark research into actionable protocols, troubleshooting, and advanced use-cases—empowering researchers to achieve high-sensitivity, reproducible data in challenging bacterial infection models.

• CDK9 Inhibitor (A3294): Technical Use and Workflow Guidance

  2026-06-02

  CDK9 inhibitor (A3294) is a selective serine/threonine kinase inhibitor designed for research applications requiring targeted transcription elongation inhibition and minimal cytotoxicity. It is not suitable for protocols demanding broad-spectrum CDK inhibition or long-term storage of working solutions.

• Bufalin: Cardiotonics Driving Advanced Cancer Research Workf

  2026-06-02

  Bufalin, a cardiotonic steroid from APExBIO, is redefining experimental cancer research by enabling precise molecular degradation and apoptosis induction in triple-negative breast cancer models. Discover optimized workflows, troubleshooting insights, and innovative protocol enhancements for leveraging Bufalin’s unique mechanisms in translational oncology.

• Alpha-Ketoglutarate in Metabolic Reprogramming: Protocols &

  2026-06-01

  Alpha-ketoglutarate (α-KGA) is revolutionizing metabolic reprogramming research with its dual roles in mitochondrial metabolism and immune modulation. This article delivers actionable workflows, troubleshooting strategies, and experimental insights drawn from cutting-edge tumor microenvironment studies and the latest protocol innovations.

• Caspase-3 Fluorometric Assay Kit: Decoding PARP1 Cleavage an

  2026-06-01

  Explore how the Caspase-3 Fluorometric Assay Kit enables advanced investigation of PARP1 cleavage and ferroptosis-apoptosis crosstalk in cancer biology. This article provides a distinct, mechanism-focused perspective on caspase-3 assay selection and interpretation.

• Q-VD(OMe)-OPh: Advancing Caspase Inhibition for Translationa

  2026-05-31

  Explore how Q-VD(OMe)-OPh transforms apoptosis research through precise, low-toxicity pan-caspase inhibition. This article offers a deep analysis of assay design, mechanistic selectivity, and translational impact, with reference to current breakthroughs and practical protocol insights.

• Amiloride (MK-870): Optimizing Sodium Channel and Endocytosi

  2026-05-30

  Amiloride (MK-870) is a dual-action inhibitor that enables precise interrogation of epithelial sodium channel and uPAR-mediated signaling in diverse cellular contexts. This guide delivers advanced protocols, troubleshooting insights, and actionable tips to accelerate ion transport and endocytosis research with APExBIO's rigorously benchmarked reagent.

• Fosinopril Sodium: Optimizing ACE Inhibition in Hypertension

  2026-05-29

  Fosinopril sodium enables reliable, high-sensitivity ACE inhibition assays with reproducible modulation of blood pressure and renal hemodynamics. Learn how to maximize its potential in cardiovascular disease models with evidence-backed protocol enhancements, troubleshooting insights, and guidance rooted in the latest translational research.

• HyperPFU™ High-Fidelity DNA Polymerase: Technical Use Guide

  2026-05-29

  HyperPFU™ high-fidelity DNA polymerase (APExBIO SKU K1031) is designed for accurate PCR amplification of long, GC-rich, or otherwise challenging DNA templates where standard enzymes may fail due to low fidelity or poor processivity. It is best suited for workflows requiring blunt-ended, error-minimized DNA products, but is not appropriate for protocols dependent on 3'-A overhangs or sticky-end ligations.

• KPT-330 (Selinexor): Optimizing CRM1 Inhibition in Cancer Re

  2026-05-28

  KPT-330 (Selinexor) stands at the forefront of targeted oncology research, enabling apoptosis induction and tumor growth inhibition through selective CRM1 blockade. This article delivers practical, evidence-driven workflows and troubleshooting strategies to maximize KPT-330’s impact in cancer cell and in vivo models.

• Probenecid (4-(dipropylsulfamoyl)benzoic acid): Applied Work

  2026-05-28

  Probenecid is more than a transporter inhibitor: it empowers high-impact workflows in multidrug resistance reversal and neuroprotection models. Explore evidence-backed protocols, troubleshooting strategies, and translational considerations for 4-(dipropylsulfamoyl)benzoic acid from APExBIO.

• Tofacitinib (CP-690550): Advanced Workflows for Immune Modul

  2026-05-27

  Tofacitinib (CP-690550) enables precise, multi-modal blockade of inflammatory cytokine signaling and mitochondrial repair in immune cell assays. Its ability to reverse GM-CSF-driven dysfunction in RA macrophages distinguishes it from conventional anti-cytokine or metabolic therapies, making it an indispensable tool for translational immune modulation research.

16872 records 1/1125 page Next 12345 下5页 Last page